The global major depressive disorder (MDD) treatment market is expected to experience steady growth, projected to develop at ...

Mizuho reiterated its bullish stance on biotech Neumora Therapeutics Inc. on Wednesday, and predicted a positive outcome when ...

A light at the end of the dark tunnel of depression? Doctors commonly prescribe antidepressants to treat patients suffering ...

Cybin (Cboe CA:CYBN) has begun its Phase 3 pivotal program, PARADIGM, to evaluate the efficacy and safety of CYB003 as an ...

UB neuroscientists have identified the binding site of low-dose ketamine, providing critical insight into how the medication ...

Patients with non-seasonal depression who were treated with bright light therapy reported a 40% remission rate, according to a recent study.

Psilocybin-assisted therapy could potentially benefit up to 5.6 million Americans with major depressive disorder or treatment ...

Cybin Inc. CYBN has launched its Phase 3 pivotal program called PARADIGM, which is aimed at testing the efficacy of its lead ...

de Filippis, R. and Al Foysal, A. (2024) Case Report: The Role of Monoamine Oxidase Inhibitors in Treating Resistant Depression. Open Access Library Journal, 11, 1-12. doi: 10.4236/oalib.1112369 .

Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revoluti ...

Cybin (TSE:CYBN) has released an update. Cybin Inc. is set to present promising 12-month data from its Phase 2 study of CYB003, aimed at ...

Bipolar disorder is a long-term mood disorder characterized by major fluctuations in mood — both high and low — that can ...